Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,890 GBX | +0.83% | -6.25% | +4.81% |
24/06 | Teva launches generic version of Novo Nordisk's diabetes drug Victoza | RE |
20/06 | Fitch Confirms Ratings, Outlook on Hikma Pharmaceuticals on 'Defensive Market Position' | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.81% | 526.07Cr | |
+55.95% | 82TCr | |
+43.62% | 64TCr | |
-6.98% | 35TCr | |
+19.08% | 33TCr | |
+9.05% | 30TCr | |
+16.30% | 24TCr | |
+2.41% | 23TCr | |
+12.47% | 22TCr | |
+8.91% | 17TCr |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Transcript : Hikma Pharmaceuticals PLC, 2023 Pre Recorded Earnings Call, Feb 22, 2024